The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study

Aims There have been no worldwide standardised surveys of prevalence and severity of asthma, rhinoconjunctivitis and eczema in school children for 15 years. The present study aims to provide this information. Methods Following the exact International Study of Asthma and Allergies in Childhood (ISAAC) methodology (cross-sectional questionnaire-based survey), Global Asthma Network (GAN) Phase I was carried out between 2015 and 2020 in many centres worldwide. Results The study included 157 784 adolescents (13–14 years of age) in 63 centres in 25 countries and 101 777 children (6–7 years of age) in 44 centres in 16 countries. The current prevalence of symptoms, respectively, was 11.0% and 9.1% for asthma, 13.3% and 7.7% for rhinoconjunctivitis and 6.4% and 5.9% for eczema. The prevalence of asthma ever was 10.5% and 7.6%, hay fever ever was 15.2% and 11.1% and eczema ever was 10.6% and 13.4%, respectively. Centres in low or lower middle gross national income countries (LICs or LMICs) had significantly lower prevalence of the three disease symptoms and diagnoses (except for hay fever). In children, the prevalence of asthma and rhinoconjunctivitis symptoms was higher in boys, while the reverse occurred among adolescents. For eczema, while the prevalence among female adolescents was double that of males, there was no sex difference among children. Centre accounted for non-negligible variability in all disease symptoms (10–20%). Conclusion The burdens of asthma, rhinoconjunctivitis and eczema vary widely among the limited number of countries studied. Although symptom prevalence is lower in LICs and LMICs, it represents a considerable burden everywhere studied.

[1]  E. Bateman,et al.  Asthma management in low and middle income countries: case for change , 2022, European Respiratory Journal.

[2]  José F. Sánchez,et al.  Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study , 2021, The Lancet.

[3]  D. Strachan,et al.  Worldwide time trends in prevalence of symptoms of rhinoconjunctivitis in children: Global Asthma Network Phase I , 2021, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[4]  Sally J. Singh,et al.  Improving lung health in low-income and middle-income countries: from challenges to solutions , 2021, The Lancet.

[5]  L. Smeeth,et al.  Atopic eczema in adulthood and mortality: UK population–based cohort study, 1998-2016 , 2021, The Journal of allergy and clinical immunology.

[6]  S. Chu,et al.  The global, regional, and national burden of fungal skin diseases in 195 countries and territories: A cross-sectional analysis from the Global Burden of Disease Study 2017 , 2020, JAAD international.

[7]  J. Bongaarts,et al.  United Nations Department of Economic and Social Affairs, Population Division World Family Planning 2020: Highlights, United Nations Publications, 2020. 46 p. , 2020 .

[8]  D. Strachan,et al.  Global Asthma Network Phase I Surveillance: Geographical Coverage and Response Rates , 2020, Journal of clinical medicine.

[9]  T. Hoashi,et al.  The Roles of Sex Hormones in the Course of Atopic Dermatitis , 2019, International journal of molecular sciences.

[10]  C. Cingi,et al.  The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions , 2018, Asia Pacific allergy.

[11]  H. Hammad,et al.  The immunology of the allergy epidemic and the hygiene hypothesis , 2017, Nature Immunology.

[12]  D. Strachan,et al.  The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors , 2017, European Respiratory Journal.

[13]  D. Nowak,et al.  Hormonal factors and incident asthma and allergic rhinitis during puberty in girls. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  D. Palmer.  Vitamin D and the Development of Atopic Eczema , 2015, Journal of clinical medicine.

[15]  U. Keil,et al.  The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. , 2013, Allergologia et immunopathologia.

[16]  M. Wickman,et al.  Eczema severity in preadolescent children and its relation to sex, filaggrin mutations, asthma, rhinitis, aggravating factors and topical treatment: a report from the BAMSE birth cohort , 2013, The British journal of dermatology.

[17]  J. Stockman.  Exposure to Environmental Microorganisms and Childhood Asthma , 2012 .

[18]  国際結核肺疾患予防連合,et al.  The global asthma report 2011 , 2011 .

[19]  D. Strachan,et al.  The impact of the method of consent on response rates in the ISAAC time trends study. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[20]  H. Williams,et al.  Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. , 2009, The Journal of allergy and clinical immunology.

[21]  H. Williams,et al.  Translation of questions: the International Study of Asthma and Allergies in Childhood (ISAAC) experience. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  S. Weiland,et al.  Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC) , 2009, Thorax.

[23]  H. R. Anderson,et al.  Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three , 2009, Allergy.

[24]  M. Worm,et al.  Impact of gender on asthma in childhood and adolescence: a GA2LEN review , 2007, Allergy.

[25]  D. Strachan,et al.  Atopic sensitization and the international variation of asthma symptom prevalence in children. , 2007, American journal of respiratory and critical care medicine.

[26]  M. Blaiss.  Allergic rhinoconjunctivitis: burden of disease. , 2007, Allergy and asthma proceedings.

[27]  D. Strachan,et al.  Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys , 2006, The Lancet.

[28]  R. Beasley,et al.  The international study of asthma and allergies in childhood (ISAAC): phase three rationale and methods. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[29]  J Crane,et al.  Agreement between written and video questions for comparing asthma symptoms in ISAAC , 2003, European Respiratory Journal.

[30]  H. CarlosJiménez,et al.  Análisis del Centro de Diagnóstico del Hospital Nacional de Niños "Dr. Carlos Saénz Herrera" , 2001 .

[31]  D. Strachan,et al.  Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. , 1999, The Journal of allergy and clinical immunology.

[32]  Richard Beasley,et al.  Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC , 1998, The Lancet.

[33]  Shah Aa.  Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC) , 1998, The European respiratory journal.

[34]  D. Strachan,et al.  International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. , 1995, The European respiratory journal.